Name: Isoniazid
Brand: Selleck Chemicals
SKU: S1937
Availability: InStock
Rating: 5 (7 reviews)

Jump to

Quality Control

Batch: Purity: 99.83%

99.83

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Fatty Acid Synthase Inhibitors	Denifanstat (TVB-2640) Fatostatin TVB-3664 C75 Betulin FT113 C75 trans Sodium palmitate IPI-9119 Desoxyrhaponticin

Solubility

In vitro
Batch:

DMSO : 27 mg/mL (196.87 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 27 mg/mL

Ethanol : 27 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.35mg/ml (9.84mM)	Taking the 1 mL working solution as an example, add 50 μL of 27 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.19mg/ml (1.39mM)	Taking the 1 mL working solution as an example, add 50 μL of 3.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	137.14	Formula	C₆H₇N₃O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	54-85-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	C1=CN=CC=C1C(=O)NN

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Isoniazid is a prodrug that requires activation by the mycobacterial catalase-peroxidase enzyme (KatG) to an active form that then exerts a lethal effect on an intracellular target or targets. This compound upregulates the expression of an operon containing five FAS II components, including kasA and acpM. It results in the accumulation of ACP-bound lipid precursors to mycolic acids that are 26 carbons long and fully saturated. This chemical enters the mycobacterial cell by passive diffusion. It itself is not toxic to the bacterial cell, but acts as a prodrug and is activated by the mycobacterial enzyme KatG, a multifunctional catalase-peroxidase that has other activities, including peroxynitritase and NADH oxidase. The agent inhibits cell wall lipid synthesis, coupled with the findings that inhibitory INH adducts of NAD+/NADP+ are formed from the isonicotinoyl radical, leading the field away from this area. It induces a concentration-dependent (0-40 mM) cytotoxic effect in day-1 treated HepG2 cells and not significantly affected by decreases in intracellular GSH concentrations.
In vivo	Isoniazid increases CYP2E1 protein, and the 6-hydroxychlorzoxazone formation rate is increased by 2.7 and 2.2-fold in liver and kidney, respectively. This compound decreases liver and kidney 20-HETE content to 34% and 15.6% of control, respectively, without significantly altering tissue 19-HETE concentration.
References	[1] https://pubmed.ncbi.nlm.nih.gov/9616124/ [2] https://pubmed.ncbi.nlm.nih.gov/11069675/ [3] https://pubmed.ncbi.nlm.nih.gov/17074073/ [4] https://pubmed.ncbi.nlm.nih.gov/9023573/ [5] https://pubmed.ncbi.nlm.nih.gov/15205388/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-03-17)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03785106	ACTIVE_NOT_RECRUITING	HIV-infected Participants With Latent TB Infection in High TB Burden Country	The HIV Netherlands Australia Thailand Research Collaboration	2019-08-15	PHASE3
NCT07656012	NOT_YET_RECRUITING	Tuberculosis	University of Wisconsin, Madison	2026-09	PHASE2
NCT07076225	NOT_YET_RECRUITING	Pulmonary Tuberculosis	Shenzhen Third People's Hospital	2025-07-25	PHASE3
NCT03474029	RECRUITING	Latent Tuberculosis	Centers for Disease Control and Prevention	2019-08-01	PHASE2; PHASE3
NCT07595042	NOT_YET_RECRUITING	Tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	2026-10-30	PHASE2
NCT06526221	ENROLLING_BY_INVITATION	Tuberculosis, Pulmonary; Medication Adherence	Tufts University	2026-04-07

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Isoniazid Fatty Acid Synthase inhibitor

Chemical Structure

Molecular Weight: 137.14